Learn why timing and muscle health are vital when using GLP-1 therapy for weight management during and after breast cancer ...

Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling efficacy and tolerability data for zovegalisib ...

About two thirds of breast cancers are classified as “hormone receptor positive” disease. These cancer cells express a group of proteins that bind to hormones, including estrogen and progesterone, ...

A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society's annual meeting in San ...

Women with breast cancer treated with complementary and alternative medicines have significantly worse survival than those receiving traditional therapies, likely due to underutilization of proven ...

The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most women with breast cancer who paused endocrine ...

More than 46% of women with stage 1 or 2 breast cancer chose to continue endocrine therapy after five years, a recent study found. The study, published in the Journal of the National Cancer Institute, ...

Preclinical studies by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, showed how a new combination therapy for hormone-resistant, ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine therapy alone. The monarchE trial showed improved OS and IDFS rates with ...